Associate Professor of Medicine, Johns Hopkins University School of Medicine
Infectious Disease
Dr. Joel N. Blankson, MD
|
|
Give Review
Joel N. Blankson works in the field of Infectious Disease. He went to Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University has a rank of 18 in research and a 49 in primary care He over the years received 1 awards: "Elected Member". Joel Blankson is a published MD as well. He has 85 publications published. The latest was: Murine monoclonal antibodies specific for conserved and non-conserved antigenic determinants of the human and murine Ku autoantigens. Joel Blankson is registered with Medicare.
Publications
- Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary.
- A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral Loads.
- Candida esophagitis in a human immunodeficiency virus-1-positive elite controller with hepatitis C virus cirrhosis.
- Finding a Cure for Human Immunodeficiency Virus-1 Infection.
- A Comparative Analysis of the Capacity of Elite Suppressor CD4+ and CD8+ T cells to Inhibit HIV-1 Replication in Monocyte-Derived Macrophages.
- HIV and HCV Activate the Inflammasome in Monocytes and Macrophages via Endosomal Toll-Like Receptors without Induction of Type 1 Interferon.
- Long term control of viral replication in a Group O, Human Immunodeficiency Virus Type 1 Infected Individual.
- HLA-B*57 Elite Suppressor and Chronic Progressor HIV-1 Isolates Replicate Vigorously and Cause CD4+ T cell Depletion in Humanized BLT Mice.
- Evolution of an Attenuated HIV-1 Isolate in an Elite Suppressor.
- Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure.
- Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay.
- The implications of viral reservoirs on the elite control of HIV-1 infection.
- Effect of Natural and ARV-Induced Viral Suppression and Viral Breakthrough on Anti-HIV Antibody Proportion and Avidity in Patients with HIV-1 Subtype B Infection.
- Inhibitory Potential of Subpopulations of CD8+ T Cells in HIV-1-Infected Elite Suppressors.
- Developing strategies for HIV-1 eradication.
- Mycobacterium tuberculosis Complex Enhances Susceptibility of CD4 T Cells to HIV through a TLR2-Mediated Pathway.
- Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation.
- Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients.
- Prolonged control of replication-competent dual tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.
- CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors.
- Viral Suppression of Multiple Escape Mutants by De Novo CD8+ T Cell Responses in a Human Immunodeficiency Virus-1 infected Elite Suppressor.
- Circulating Monocytes Are Not a Major Reservoir of HIV-1 in Elite Suppressors.
- Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy.
- The study of elite controllers: a pure academic exercise or a potential pathway to an HIV-1 vaccine?
- HIV type 1-mediated downregulation of HLA-B*57/B*5801 proteins on elite suppressor CD4+ T cells.
- Killing the messenger to maintain control of HIV.
- Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection.
- Prolonged control of an HIV type 1 escape variant following treatment interruption in an HLA-B*27-positive patient.
- Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.
- Control of HIV-1 replication in elite suppressors.
- A case of seronegative HIV-1 infection.
- HIV-1 evolution following transmission to an HLA-B*5801-positive patient.
- T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors.
- A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy.
- Effective downregulation of HLA-A*2 and HLA-B*57 by primary human immunodeficiency virus type 1 isolates cultured from elite suppressors.
- Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus ty...
- Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-B*57+ elite suppressors.
- Elite suppression of HIV-1 replication.
- Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell act...
- Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor.
- A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy.
- CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load.
- Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors.
- An atypical case of fatal zygomycosis: simultaneous cutaneous and laryngeal infection in a patient with a non-neutropenic solid prostatic tumor.
- Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape.
- Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors.
- Report from Los Angeles: the 14th Conference on Retroviruses and Opportunistic Infections (CROI). CD4 lymphocyte depletion: where have all the cells gone?
- Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations.
- Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on hig...
- Viral reservoirs and HIV-specific immunity.
- Crosscurrents in HIV-1 evolution.
- The Effect of early treatment on the latent reservoir of HIV-1.
- Primary HIV-1 infection: to treat or not to treat?
- Early treatment of HIV.
- Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients.
- The challenge of viral reservoirs in HIV-1 infection.
- Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening.
- CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants.
- Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells.
- Molecular analysis of autoantibody production.
- Murine monoclonal antibodies specific for conserved and non-conserved antigenic determinants of the human and murine Ku autoantigens.
- HIV-1 and hematopoietic stem cell transplantation.
- Interleukin 2 treatment for HIV infection.
- Latent reservoirs for HIV-1.
- Report from Boston: the 12th Conference on Retroviruses and Opportunistic Infections (CROI). The New York City patient: a case of progression, pathogenesis, and public...
- Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
- Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2.
- Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1.
- MHC class II genotype and the control of viremia in HIV-1-infected individuals on highly active antiretroviral therapy.
- Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution.
- Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection.
- Superantigens and conventional antigens induce different responses in alpha beta T-cell receptor transgenic mice.
- The CD28/B7 pathway costimulates the response of primary murine T cells to superantigens as well as to conventional antigens.
- Structured therapeutic interruptions: a review.
- Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs.
- The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors.
- Low frequency of GB virus C viremia in a cohort of HIV-1-infected elite suppressors.
- Elucidating the elite: mechanisms of control in HIV-1 infection.
- Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses?
- HIV-1 Gag evolution in recently infected human leukocyte antigen-B*57 patients with low-level viremia.
- Seronegative HIV-1 infection: a review of the literature.
- Evolution of the HIV-1 nef gene in HLA-B*57 positive elite suppressors.
- Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/sup...
- Spontaneous resolution of HIV-associated nephropathy in an elite controller.
Schools
Weill Cornell Medical College
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Choice Advantage
- Blue Choice Network POS
- Blue Preferred PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Southern Health PPO
- Coventry Health Care of Delaware PPO
- Emblem Health
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- Choice Care PPO
- Kaiser Permanente
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Options PPO
Awards
- Elected Member
Education
-
Johns Hopkins University -
Weill Cornell Medical College of Cornell University
Hospital
-
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1699731703 | |
| NPPES Provider LastName | BLANKSON | |
| NPPES Provider FirstName | JOEL | |
| NPPES Provider ZIPCode | 210934515 | |
| NPPES Provider State | MD | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 1231.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1699731703 |
| Last Name Of The Provider | BLANKSON |
| First Name Of The Provider | JOEL |
| View All |
Similar Doctors
|
|
Dr. Melissa L. Fox, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel E. Gallant, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Paul G. Auwaerter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher J. Hoffmann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Aucott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie B. Trivedi, MD
This Doctor is OpenDoctor Recommended.
|